REDLAMP 5: Rituximab vs. Watch & Wait Approach in Patients with Advanced Follicular Lymphoma

Conventional therapy for patients with advanced stage, low tumor burden follicular lymphoma can include watchful waiting until the disease progresses. In this video Dr. Kelly Trevino explains the findings of a study in Lancet Oncology that assessed the difference in quality of life for patients who used rituximab to delay chemotherapy treatment and those patients who took the watchful wait approach.

Previous #REDLAMP entries can be viewed on our Youtube channel.

We encourage you to follow the Lymphoma Program on Twitter, Youtube, and Facebook where we will highlight new videos are about research publications as they are released. We also welcome your feedback, suggestions and questions about this project. If you have other questions about our lymphoma program or clinical trials or would like to see one of our lymphoma specialists, please contact us at 646-962-2074.

Author: lymphomaprogram

Located on the Upper East Side of New York City, the Lymphoma Program at Weill Cornell Medical College/NewYork Presbyterian Hospital is internationally recognized for our efforts to enable patients with non-Hodgkin lymphoma, Hodgkin disease and related disorders to have the best possible clinical outcome, including cure when possible. View all posts by lymphomaprogram